Tuesday, September 16, 2014 9:32:31 PM
Posted by AGORACOM-JC at 8:06 AM on Thursday, August 28th, 2014
KELOWNA, BC / August 28, 2014 / Lexaria Corp. (OTCQB: LXRP) (CSE: LXX) (the “Company” or “Lexaria” or “our” or “Lexaria CanPharm Corp”) announces our new corporate policies regarding the responsible use of medical marijuana.
In Canada, the MMPR legislation governed by Health Canada provides the framework by which qualified persons can access marijuana for medical purposes. Recently, the Supreme Court of British Columbia has also ruled that medical marijuana is a constitutional right for persons in need, deliverable in forms commonly referred to as “oils and edibles”. Lexaria intends to comply with the laws and regulations within every jurisdiction in which it might operate.
In addition, it is our philosophy to recognize the potential for harm within this sensitive industry and to build a set of corporate policies that go above and beyond those required by law. Lexaria is leading the industry with these policies.
Therefore, Lexaria is establishing a corporate policy wherein we will not knowingly sell medical cannabis containing more than 0.3% THC to any medical marijuana patient who is under the age of 21, unless it is in a form specifically approved by relevant government health agencies.
“Our goal is to safely help people live healthy and productive lives,” said Chris Bunka, CEO of Lexaria. “We want to be sure to do no harm and Lexaria’s policies are a big step in the right direction – ensuring members of our community are receiving the health benefits they need.”
Broadly speaking, there are two main ‘families’ of active ingredients in marijuana: THC (Tetrahydrocannabinol) which have primarily psychoactive properties accompanied by possible medicinal qualities; and CBD (Cannabidiol) which are believed to have more significant medicinal properties and do NOT generally have psychoactive properties. Introductory information about Cannabidiol can be found at Wikipedia at http://en.wikipedia.org/wiki/Cannabidiol
Our underage policy makes Lexaria’s and Lexaria CanPharm’s medical marijuana sales policies more restrictive than Canada’s alcohol consumption laws; and broadly in line with the USA’s alcohol consumption laws. We believe it would not be responsible to provide medical marijuana with THC-psychoactive properties to underage persons, so long as there is a CBD-based available alternative with medical properties that can meet a potential patient’s needs. We would welcome any development that sees the medical marijuana industry sector follow our lead on this issue and restrict the selling of marijuana containing THC to underage persons.
Many health care practitioners are reluctant to support the use of medical marijuana in underage patients, and it is our hope that our underage policy helps to address those concerns.
Also, Lexaria does not encourage nor support consuming marijuana through the act of smoking. Some research has indicated that the act of burning marijuana may negatively affect the delivery of potentially helpful CBD-based compounds, and smoking any substance is not conducive to good health practices. Lexaria’s policy, for those who require medical marijuana, is to encourage its consumption through edible and other legal forms that do not require smoking.
Lexaria encourages persons across Canada or in the USA whose philosophy regarding the responsible use of marijuana is in accordance with our own, to register at our website (www.lexariaenergy.com). Lexaria wishes to build a community of like-minded, responsible medical users of marijuana who can share their experiences and knowledge with each other for the benefit of all. Lexaria CanPharm Corp is in the development stages of a new website which will be announced when complete.
Lexaria reminds all parties that it does not currently posses a production license under Health Canada’s MMPR program, nor in any other jurisdiction, and cannot fill any medical marijuana prescription orders at this time.
About Lexaria
Lexaria’s shares are quoted in the USA with symbol LXRP and in Canada with symbol LXX. The company searches for projects that could provide potential above-market returns.
To learn more about Lexaria Corp. visit www.lexariaenergy.com.
FOR FURTHER INFORMATION PLEASE CONTACT:
Lexaria Corp.
Chris Bunka
Chairman & CEO
(250) 765-6424
Recent LEXX News
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/06/2024 11:00:40 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 07:28:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:30:59 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 02/16/2024 08:47:26 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:20:50 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 05:00:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 06:51:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/24/2024 07:12:07 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 01/24/2024 06:33:08 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/18/2024 07:38:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/12/2024 10:11:16 PM
- Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream • GlobeNewswire Inc. • 01/11/2024 01:30:00 PM
- Beyond Diabetes, a Blockbuster Horizon Beckons • InvestorsHub NewsWire • 01/10/2024 01:45:00 PM
- Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform • GlobeNewswire Inc. • 01/09/2024 01:30:00 PM
- Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs • InvestorsHub NewsWire • 01/08/2024 01:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 10:07:45 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 11/30/2023 09:14:31 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 11/20/2023 10:16:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 05:13:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/01/2023 05:45:34 PM
- Get Ready for Next Generation of Diabetes, Weight-Management Drugs • InvestorsHub NewsWire • 11/01/2023 12:45:00 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM